Korea Q2 Roundup: New Drugs Drive Growth, First-Line Lazertinib Approval

New Indications For U-Turned Assets, 'Glocalization'

 
• By Jung Won Shin
  
Quarterly report
Hanmi, SK Biopharm Seek New Road Maps For Growth As Q2 results announced • Source: Shutterstock

More from South Korea

More from Focus On Asia